Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report

FGFR3-TACC3 fusions have been identified in patients with multiple cancer types, and tumors with these alterations are potentially sensitive to selective FGFR inhibitors. However, there are no FGFR inhibitors approved by the U.S. Food and Drug Administration for the treatment of patients with NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Chi, Lang, Daenielle, Iams, Wade T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192640/
https://www.ncbi.nlm.nih.gov/pubmed/37214414
http://dx.doi.org/10.1016/j.jtocrr.2023.100511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192640/
https://www.ncbi.nlm.nih.gov/pubmed/37214414
http://dx.doi.org/10.1016/j.jtocrr.2023.100511

Ejemplares similares